The Effect of Vitamin E Supplementation on Cardiovascular Risk in Diabetic Individuals With Different Haptoglobin Phenotypes
- Andrew P. Levy, MD, PHD1,
- Hertzel C. Gerstein, MD, MSC2,
- Rachel Miller-Lotan, PHD1,
- Robert Ratner, MD3,
- Matthew McQueen, MBCHB2,
- Eva Lonn, MD2 and
- Janice Pogue, MSC2
- 1Technion Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
- 2Department of Medicine and Population Health Research Institute, Hamilton Health Sciences and McMaster University, Hamilton, Ontario, Canada
- 3MedStar Research Institute, Washington D.C.
- Address correspondence to Andrew P. Levy MD, PhD, Technion Faculty of Medicine, Haifa, Israel. E-mail: alevy{at}tx.technion.ac.il
Several clinical trials (1) have demonstrated that vitamin E does not reduce future major cardiovascular (CV) events. However, these trials could not rule out the potential benefit for high-risk subgroups. Diabetic individuals who are homozygous for the haptoglobin 2 allele (Hp 2-2) are at high risk for CV events (2–4); moreover, the Hp 2-2 protein product is an inferior antioxidant compared with …
